Patents by Inventor Charles Eric Mowbray

Charles Eric Mowbray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11691992
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: July 4, 2023
    Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the Army
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • Publication number: 20210253605
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Application
    Filed: February 11, 2021
    Publication date: August 19, 2021
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • Patent number: 10961261
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: March 30, 2021
    Assignees: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretaryof the Army
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • Publication number: 20200024289
    Abstract: This application describes compounds, compositions, and methods which are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite.
    Type: Application
    Filed: March 1, 2018
    Publication date: January 23, 2020
    Applicants: Anacor Pharmaceuticals, Inc., The Government of the United States, as represented by the Secretary of the Army, The Government of the United States, as represented by the Secretary of the Army
    Inventors: Robert Toms Jacobs, Yang Liu, Richard J. Sciotti, Jason D. Speake, Gavin Alistair Whitlock, Paul Alan Glossop, Charles Eric Mowbray, Delphine Françoise Monique Launay, Stephen John Robinson
  • Publication number: 20120029192
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Application
    Filed: October 7, 2011
    Publication date: February 2, 2012
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Patent number: 8063044
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: November 22, 2011
    Assignee: Pfizer Inc.
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Patent number: 7943628
    Abstract: A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R1, R2, R3, R4, R5, and R8 are as defined above.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: May 17, 2011
    Assignee: Pfizer Limited
    Inventors: Andrew Simon Bell, Charlotte Alice Louise Lane, Charles Eric Mowbray
  • Publication number: 20090264425
    Abstract: This invention relates to biaryl ether derivatives of formula (I) wherein R1, R3, R4, X, W, Y and m are defined in the description, and to compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof.
    Type: Application
    Filed: December 12, 2005
    Publication date: October 22, 2009
    Inventors: Lyn Howard Jones, Donald Stuart Middleton, Charles Eric Mowbray, Sandra Dora Newman, David Howard Williams
  • Publication number: 20090215712
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Application
    Filed: August 25, 2008
    Publication date: August 27, 2009
    Inventors: Lyn Howard JONES, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Patent number: 7435728
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: October 14, 2008
    Assignee: Pfizer Inc
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Publication number: 20080132549
    Abstract: This invention relates to isophthalonitrile derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R3 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof.
    Type: Application
    Filed: April 11, 2005
    Publication date: June 5, 2008
    Applicant: Pfizer Inc.
    Inventors: Lyn Howard Jones, Shahid Mohammed, Sandra Newman, Charles Eric Mowbray, Matthew Ducan Selby, Paul Anthony Stupple, Nigel Alan Swain
  • Patent number: 7220772
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: May 22, 2007
    Assignee: Pfizer, Inc.
    Inventors: Paul John Edwards, Lyn Howard Jones, Charles Eric Mowbray, Paul Anthony Stupple, Isabelle Tran
  • Patent number: 7157468
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4, n W, X and Y are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: September 23, 2003
    Date of Patent: January 2, 2007
    Assignee: Pfizer Inc.
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Patent number: 7141585
    Abstract: This invention relates to the use of pyrazole derivatives of the formula and pharmaceutically acceptable salts and solvates thereof, in the manufacture of a reverse transcriptase inhibitor or modulator, to certain novel such pyrazole derivatives and to processes for the preparation of and compositions containing such novel derivatives.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: November 28, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Romuald Gaston Corbau, Charles Eric Mowbray, Manoussos Perros, Paul Anthony Stupple, Anthony Wood
  • Patent number: 7109228
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: September 19, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Publication number: 20040209862
    Abstract: This invention relates to the use of pyrazole derivatives of the formula 1
    Type: Application
    Filed: April 26, 2004
    Publication date: October 21, 2004
    Applicant: PFIZER, INC.
    Inventors: Romuald Gaston Corbau, Charles Eric Mowbray, Manoussos Perros, Paul Anthony Stupple, Anthony Wood
  • Publication number: 20040132793
    Abstract: This invention relates to the pyrazole derivatives of formula (I) 1
    Type: Application
    Filed: September 12, 2003
    Publication date: July 8, 2004
    Applicant: Pfizer Inc.
    Inventors: Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Patent number: 6750230
    Abstract: This invention relates to the use of pyrazole derivatives of the formula and pharmaceutically acceptable salts and solvates thereof, in the manufacture of a reverse transcriptase inhibitor or modulator, to certain novel such pyrazole derivatives and to processes for the preparation of and compositions containing such novel derivatives.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: June 15, 2004
    Assignee: Pfizer, Inc.
    Inventors: Romuald Gaston Corbau, Charles Eric Mowbray, Manoussos Perros, Paul Anthony Stupple, Anthony Wood
  • Publication number: 20030100554
    Abstract: This invention relates to pyrazole derivatives of formula (I) 1
    Type: Application
    Filed: April 5, 2002
    Publication date: May 29, 2003
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Patent number: 6376490
    Abstract: The invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein R is a 5-membered ring heteroaryl group containing 3 or 4 nitrogen heteroatoms which is linked to the quinoxalinedione ring by a ring carbon or nitrogen atom said group being optionally benzo-fused and optionally substituted, including in the benzo-fused portion, by 1 or 2 substituents each independently selected from C1-C4 alkyl, C2-C4 alkenyl, C3-C7 cycloalkyl, halo, hydroxy, C1-C4 alkoxy, C3-C7 cycloalkyloxy, —COOH, C1-C4 alkoxycarbonyl, —CONR3R4, —NR3R4, —S(O)p(C1-C4 alkyl), —SO2NR3R4, aryl, aryloxy, aryl(C1-C4)alkoxy, and het, said C1-C4alkyl being optionally substituted by C3-C7 cycloalkyl, halo, hydroxy, C1-C4 alkoxy, halo(C1C4)alkoxy, C3-C7 cycloalkyloxy, C3-C7 cycloalkyl (C1-C4) alkoxy, —COOH, C1-C4 alkoxycarbonyl, —CONR3R4, —NR3R4,—S(O)p(C1-C4 alkyl), —SO2(aryl), —SO2NR3R4 morpholino, aryl, aryloxy, aryl(C1-C4)
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: April 23, 2002
    Assignee: Pfizer Inc
    Inventors: David John Bull, Christopher Lee Carr, Michael Jonathan Fray, Elisabeth Colette Louise Gautier, Charles Eric Mowbray, Alan Stobie